Risk adjusted net present value: What is the current valuation of Novo Nordisk’s NNC0519-0130?

NNC0519-0130 is commercialized by Novo Nordisk, with a leading Phase II program in Type 2 Diabetes.

Related Posts

STAT+: Like a vampire, some cancer cells can suck the e...

Oct 14, 2023

Rallybio and J&J collaborate to tackle maternal-foetal ...

Apr 13, 2024

Bavarian Nordic expands access to mpox vaccine in US

Apr 3, 2024